Neosoma Platform
Overview
The Neosoma Platform is a cloud-based software medical device designed to support neuro-oncology clinical teams, researchers, and clinical trials. It offers a portfolio of highly-optimized, indication-specific tools that map and measure tumor compartments and track lesions longitudinally. The platform delivers key insights in near real-time to aid clinical decisions and research.
Neosoma’s technology seamlessly integrates with PACS for automated DICOM study analysis and supports one-click deep linking from PACS to the Neosoma system. It is built for efficiency, providing per-timepoint and per-patient reports, a brain mets lesion review wizard, smart editing tools, and quick visuals for patient communication. The platform is highly tolerant of real-world MRI data, requiring no changes to existing MRI acquisition protocols and readily accepting prior patient studies.
Security and compliance are central to the Neosoma Platform. It is SOC2 Type II certified, HIPAA compliant, and designed with best-in-class security practices. The web-based interface ensures easy and secure access. Furthermore, the platform is interoperable with various radiation treatment and surgical planning systems, allowing easy import of lesion contours (GTVs) into systems like Eclipse, MIM, Gamma Plan, and Stealth.
The Neosoma Platform is currently FDA cleared for Gliomas and Brain Metastases. It offers a reimbursement pathway through available Category 3 CPT Codes (0865T, 0866T) for each MRI timepoint analysis. The pricing model is based on MRI volume, allowing multiple multidisciplinary team members to have logins without incremental seat licenses, fostering adoption and usage across the practice.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- PACS Integration
- Automated DICOM study analysis
- Longitudinal lesion tracking
- Real-time insights for clinical decisions
- MRI Protocol Tolerant (no changes needed)
- SOC2 Type II certified and HIPAA compliant
- Interoperable with treatment planning systems (Eclipse, MIM, Gamma Plan, Stealth)
- Interactive 3D/2D visualizations and smart editing tools
- Reimbursable (Category 3 CPT Codes 0865T, 0866T)
- Cloud-based and scalable
Use Cases
- Tumor mapping and measurement for neuro-oncology
- Longitudinal tracking of brain metastases and gliomas
- Supporting clinical decisions in neuro-oncology
- Research and clinical trials in neuro-oncology
- Importing lesion contours into radiation treatment and surgical planning systems
- Efficient reporting and patient communication
What Physicians Need to Know
Utilize Neosoma's differential diagnosis support to explore less common neurovascular conditions. Leverage the platform's evidence base to quickly access relevant literature and guidelines, especially in rapidly evolving areas of neurovascular care. Integrate the platform's insights early in the diagnostic process to optimize treatment planning.
The Neosoma Platform is designed for integration with various hospital information systems and electronic health records (EHRs) to facilitate data exchange and embed its decision support directly within the physician's existing digital environment. Specific integration capabilities may vary based on the healthcare system's infrastructure.
Details
| Category | Clinical Decision Support & Reference, Oncology AI, Radiology & Imaging AI |
| Pricing |
Volume-based
|
| Deployment | Cloud |
| Mobile App | No |
| Data Export | Yes |
| Languages | English |
| Compliance | |
| BAA Available | Yes AI-estimated |
| HIPAA Compliant | Yes AI-estimated |
| FDA Status |
Cleared AI-estimated FDA cleared for Gliomas and Brain Metastases. Neosoma Glioma and Neosoma Brain Mets are FDA cleared. |
| SOC 2 | Yes AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Neurology Ai, Oncology Ai |
Social Proof
| Customers | unknown |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Neosoma Platform
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Neosoma Platform.
Frequently Asked Questions
Compare Neosoma Platform
VS
VS
VS
Investors who backed Neosoma Platform
Funded through the company that built this tool.
